About AGRX
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen ... [Read more]
Industry
Sector Healthcare
IPO Date May 23, 2014
Employees 19
Stock Exchange OTCMKTS
Ticker Symbol AGRX
Full Company Profile
Financial Performance
In 2023, AGRX's revenue was $19.59 million, an increase of 80.02% compared to the previous year's $10.88 million. Losses were -$14.47 million, -43.08% less than in 2022.
Financial Statements
Analyst Forecast
According to 2 analysts, the average rating for AGRX stock is "Buy." The 12-month stock price forecast is $12.0, which is an increase of 739.16% from the latest price.
Price Target
$12.0
(739.16% upside)
Analyst Consensus: Buy
Stock Forecasts
News
AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Agile Therapeutics, Inc. (OTCQB: AGRX) to Insud Pharma, S.L. for $1.52 per share in cash ...
1 day ago - Business Wire
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio
1 day ago - GlobeNewsWire
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (G...
6 weeks ago - GlobeNewsWire
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in ...
3 months ago - GlobeNewsWire
Agile Therapeutics Announces Delisting from Nasdaq
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has ...
3 months ago - GlobeNewsWire
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.(Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial re...
3 months ago - GlobeNewsWire
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.(Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial re...
3 months ago - GlobeNewsWire
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
Elimination of Remaining Debt to Perceptive Advisors Leaves the Company's Balance Sheet Debt Free Elimination of Remaining Debt to Perceptive Advisors Leaves the Company's Balance Sheet Debt Free
3 months ago - GlobeNewsWire
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a defin...
4 months ago - GlobeNewsWire
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance Update
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024
4 months ago - GlobeNewsWire
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women
5 months ago - GlobeNewsWire
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act's No-Cost Contraceptive Coverage Requirement
The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps
7 months ago - GlobeNewsWire
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year...
7 months ago - Accesswire
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 202...
8 months ago - GlobeNewsWire
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J.
8 months ago - GlobeNewsWire
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the granting of a previously disclosed inducement award to the...
9 months ago - GlobeNewsWire
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
PRINCETON, NJ / ACCESSWIRE / September 28, 2023 / Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the ...
9 months ago - Accesswire
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and ...
10 months ago - GlobeNewsWire
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
PRINCETON, NJ / ACCESSWIRE / August 17, 2023 / On August 9, Agile Therapeutics (NASDAQ:AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative we...
11 months ago - Accesswire
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to F...
11 months ago - GlobeNewsWire
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.(Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before th...
1 year ago - GlobeNewsWire
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
PRINCETON, NJ / ACCESSWIRE / July 19, 2023 / Agile Therapeutics, Inc.'s (NASDAQ:AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women's healthcare company toward ...
1 year ago - Accesswire
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive Coverage
PRINCETON, NJ / ACCESSWIRE / July 11, 2023 / - In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services . It di...
1 year ago - Accesswire
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
PRINCETON, NJ / ACCESSWIRE / July 5, 2023 / H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ:AGRX) this month, setting a price target of $12 per share.
1 year ago - Accesswire
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Agile Says Growing Demand For Twirla (levonorgestrel and ethinyl estradiol) transdermal system Is Helping It Stay On Track to Hit $25-$30 Million Net Revenue PRINCETON, NJ / ACCESSWIRE / July 3, 2023...
1 year ago - Accesswire
